Abstract: Oxide semiconductor photodetectors (PDs) are frequently employed in applications such as the Internet of Things (IoT) due to their high mobility and low off-state current. To balance ...

Scientists have found a way to push zinc–bromine flow batteries to the next level. By trapping corrosive bromine with a simple molecular scavenger, they were able to remove a major barrier to the ...

A research team has revealed a breakthrough in enhancing the performance of zinc-air batteries (ZABs), a significant energy storage technology, in a study published in Energy & Environmental Science.

A recent study published in Advanced Science reports a strategy to improve aqueous zinc-iodine (Zn-I 2) batteries. These batteries are valued for their low cost, safety, and long cycle life. Despite ...

With the growing global demand for energy, safe and efficient energy storage technologies have become crucial for advancing renewable energy development. In recent years, rechargeable aqueous zinc ...

Molybdenum carbide (MoC) nanoclusters embedded in porous nitrogen-doped carbon fibers with atomic Zn-N4 sites exhibit a physicochemical confinement effect on iodine species and enhance electron/ion ...

Rechargeable aqueous zinc-iodine batteries get a lot of attention because they are safe, do not cost much, and have a high theoretical capacity. Zinc has a high theoretical capacity (820 mAh g-1) and ...

Zinc-based batteries are rechargeable, using zinc as the anode material. During discharge, zinc atoms oxidize, releasing zinc ions that travel through the electrolyte to the cathode, where they are ...

College of Chemistry and Chemical Engineering, State-Province Joint Engineering Laboratory of Power Source Technology for New Energy Vehicle, Tan Kah Kee Innovation Laboratory (IKKEM), State Key ...

HONG KONG & SUZHOU, China & SHANGHAI--(BUSINESS WIRE)--Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has ...

Roche AG acquired global rights to Zion Pharma Ltd.’s lead program, ZN-A-1041, an orally administered selective tyrosine kinase inhibitor that is designed to penetrate the blood-brain barrier and can ...